Regulation of tissue factor pathway inhibitor-2 (TFPI-2) expression by lysine-specific demethylase 1 and 2 (LSD1 and LSD2)

@article{Mino2014RegulationOT,
  title={Regulation of tissue factor pathway inhibitor-2 (TFPI-2) expression by lysine-specific demethylase 1 and 2 (LSD1 and LSD2)},
  author={Koshiki Mino and Satoshi Nishimura and Shogo Ninomiya and Hiroshi Tujii and Yasumasa Matsumori and Mie Tsuchida and Miho Hosoi and Koichi Koseki and Shu-ichi Wada and Makoto Hasegawa and Ryuzo Sasaki and Yukie Murakami-Yamaguchi and Hiroshi Narita and Takayoshi Suzuki and Naoki Miyata and Tamio Mizukami},
  journal={Bioscience, Biotechnology, and Biochemistry},
  year={2014},
  volume={78},
  pages={1010 - 1017}
}
Tissue factor pathway inhibitor-2 (TFPI-2) is a major inhibitor of extracellular matrix degradation. Decreases in TFPI-2 contribute to malignant tumor cell production, and TFPI-2 is a presumed tumor suppressor. TFPI-2 gene transcription is regulated by two epigenetic mechanisms: DNA methylation of the promoter and K4 methylation of histone 3 (H3). Lysine-specific demethylase 1 (LSD1) and LSD2 demethylate H3K4me2/1. LSD1 has been implicated in TFPI-2 regulation through both epigenetic mechanisms… 

Lysine-specific demethylase 2 contributes to the proliferation of small cell lung cancer by regulating the expression of TFPI-2

The results suggest that LSD2 achieves a promoting effect on SCLC by indirectly regulating TFPI-2 expression through the mediation of DNMT3B expression or through the regulation of the demethylation of H3K4me1 in the promoter region of the TFPi-2 gene.

LSD 2 / KDM 1 B / AOF 1 and Human Cancer Pathways : A Literature Review

Five major studies on LSD2 in cancer indicate that LSD2 may play multiple roles in human cancer cell survival and may play a crucial role in understanding pathways that illuminate novel treatments for human cancer.

Structural insight into inhibitors of flavin adenine dinucleotide-dependent lysine demethylases

This review focuses on published small-molecule inhibitors targeted at the two flavin adenine dinucleotide-dependent lysine demethylase 1 and 2, and how the inhibitors interact with the tertiary structures of the enzymes.

S‐adenosylmethionine in combination with decitabine shows enhanced anti‐cancer effects in repressing breast cancer growth and metastasis

The combined therapeutic effects of an approved nutraceutical agent S‐adenosylmethionine and FDA‐approved hypomethylating agent decitabine using the MDA‐MB‐231 xenograft model of breast cancer is investigated and found a pronounced reduction in mammary tumour volume and lung metastasis compared to the animals in the control and monotherapy treatment arms.

Tissue Factor Pathway Inhibitor-2 Gene Polymorphisms Associate With Coronary Atherosclerosis in Chinese Population tissue factor–factor

There was not enough evidence showing that the information about TFPI-2 gene polymorphisms was useful for assessing the risk of developing coronary atherosclerosis, but there was notenough evidence showing it could predict occurrence of CVE.

Tissue Factor Pathway Inhibitor-2 Gene Polymorphisms Associate With Coronary Atherosclerosis in Chinese Population

Tissue factor pathway inhibitor-2 gene polymorphisms were associated with coronary atherosclerosis in the Chinese population, suggesting that the information about TFPI-2 Gene polymorphisms was useful for assessing the risk of developing coronary Atherosclerosis, but there was not enough evidence showing it could predict occurrence of CVE.

Identification of ryuvidine as a KDM5A inhibitor

Ryuvidine may serve as a lead compound for KDM5 targeted therapeutics after it was found that ryuvidine prevented generation of gefitinib-tolerant human small-cell lung cancer PC9 cells and also inhibited the growth of the drug-Tolerant cells at concentrations that did not affect thegrowth of parentalPC9 cells.

Interaction between tissue factor pathway inhibitor-2 gene polymorphisms and environmental factors associated with coronary atherosclerosis in a Chinese Han

The GMDR model shown the best models for gene–environment interaction were rs34489123 and smoking after adjusting the covariates, which scored 10 out of 10 for cross-validation consistency and 0.0010 for the sign test.

References

SHOWING 1-10 OF 35 REFERENCES

Promoter methylation and silencing of the tissue factor pathway inhibitor-2 (TFPI-2), a gene encoding an inhibitor of matrix metalloproteinases in human glioma cells.

It is established that TFPI-2 is transcriptionally silenced through promoter methylation in SNB19 cells.

Promoter methylation and silencing of the tissue factor pathway inhibitor-2 (TFPI-2), in human glioma cells

It is established that TFPI-2 is transcriptionally silenced through promoter methylation in SNB19 cells.

Overexpression of tissue factor pathway inhibitor-2 (TFPI-2), decreases the invasiveness of prostate cancer cells in vitro.

This is the first demonstration that upregulation of TFPI-2 plays a significant role in the invasive behavior of human prostate cancer cells.

Transcriptional Silencing of the TFPI-2 Gene by Promoter Hypermethylation in Choriocarcinoma Cells

It is demonstrated that DNA demethylation by 5'-aza-2'-deoxycytidine restores TFPI-2 transcription in JAR choriocarcinoma cells and concluded that hypermethylation of the TFPi-2 gene is correlated with transcriptional silencing and that the TLP2 gene may be a candidate tumor suppressor gene.

Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy.

First evidence that a histone demethylase, LSD1, is involved in maintaining the undifferentiated, malignant phenotype of neuroblastoma cells is provided, showing that inhibition of LSD1 reprograms the transcriptome of neuro Blastoma cells and inhibits Neuroblastoma xenograft growth in vivo.

In vitro modulation of human lung cancer cell line invasiveness by antisense cDNA of tissue factor pathway inhibitor-2

The data suggest that TFPI-2 is critical for the invasion and metastasis of lung cancer and that the downregulation of TFPi-2 production may be a feasible approach to increase invasiveness and metastases.

Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers

Investigation of exogenous LSD1 expression promoted cell cycle progression of human embryonic kidney fibroblast cells and showed that LSD1 could affect the expression of genes involved in various chromatin‐modifying pathways such as chromatin remodeling at centromere, centromeric heterochromatin formation and chromatin assembly, indicating its essential roles in carcinogenesis through chromatin modification.

trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1.

It is shown that 2-PCPA is a time-dependent, mechanism-based irreversible inhibitor of LSD1 with a KI of 242 microM and a kinact of 0.0106 s-1, which will provide a foundation for the design of cyclopropylamine-based inhibitors that are selective for LSD1 to probe its role in vivo.

KDM1B is a histone H3K4 demethylase required to establish maternal genomic imprints

It is suggested that demethylation of H3K4 is critical for establishing the DNA methylation imprints during oogenesis, and amine oxidase (flavin-containing) domain 1 (AOF1), a protein related to the lysine demethylase KDM1 (also known as LSD1), functions as a histone H3Lysine 4 (H3K 4) demethyl enzyme and is required for de novo DNA methylated genes in oocytes